trending Market Intelligence /marketintelligence/en/news-insights/trending/Oe6H75ut3wtmSBIIbsET_A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Spectrum submits updated application for blood disorder drug to US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Spectrum submits updated application for blood disorder drug to US FDA

Spectrum Pharmaceuticals Inc. submitted an updated biologics license application to the U.S. Food and Drug Administration for Rolontis after voluntarily withdrawing an earlier submission in March.

The Henderson, Nev.-based biotech is seeking approval for its blood disorder drug Rolonits, or eflapegrastim, to treat chemotherapy-induced neutropenia. Neutropenia is an abnormally low concentration of neutrophils, a type of white blood cell, in the blood due to chemotherapy. The destruction of these cells leaves the body vulnerable to infections.

Spectrum, which develops therapies to treat cancer and blood disorders, initially submitted an application with the FDA in December 2018 but withdrew it after the U.S. regulator requested additional manufacturing-related information for the medicine. The updated application includes additional information regarding chemistry, manufacturing and controls.

The application is based on results from two phase 3 studies dubbed Advance and Recover that showed Rolontis and Amgen Inc.'s Neulasta, or pegfilgrastim, had no meaningful differences.